Return of the Coronavirus: 2019-nCoV.
Gralinski LE, Menachery VD. · 2020
Read Return of the Coronavirus: 2019-nCoV. by Gralinski LE, Menachery VD. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7077245.txt.
Introduction
Gralinski and Menachery review the return of coronavirus in the journal Viruses. A novel coronavirus, 2019-nCoV, emerged in December 2019 among patients connected to the Huanan South China Seafood Market in Wuhan. It was the third zoonotic human coronavirus of the century, after SARS-CoV and MERS-CoV. Patients showed viral pneumonia: fever, difficult breathing, and, in severe cases, infiltration of both lungs.
Chinese authorities closed and decontaminated the market on 1 January 2020, and the virus was identified within days, first in one patient and then verified in 16 more. The review asks whether the world is better equipped this time. Early absence of infections in health care workers hinted at inefficient human spread, a hopeful sign the authors already doubted as case counts climbed and market links thinned. The source of the virus remained unknown, which they flag as the key missing fact.
Catalog record
| CREATOR | Gralinski LE, Menachery VD. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Return of the Coronavirus: 2019-nCoV By Lisa E. Gralinski, Vineet D. Menachery Published in: Viruses DOI: 10.3390/v12020135 ABSTRACT The emergence of a novel coronavirus (2019-nCoV) has awakened the echoes of SARS-CoV from nearly two decades ago. Yet, with technological advances and important lessons gained from previous outbreaks, perhaps the world is better equipped to deal with the most recent emergent group 2B coronavirus. 1. EMERGENCE The third zoonotic human coronavirus (CoV) of the century emerged in December 2019, with a cluster of patients with connections to Huanan South China Seafood Market in Wuhan, Hubei Province, China. Similar to severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) infections, patients exhibited symptoms of viral pneumonia including fever, difficulty breathing, and bilateral lung infiltration in the most severe cases [1]. News reports of patients with an unknown pneumonia were first identified on 31st December with the Wuhan Municipal Health Commission saying they were monitoring the situation closely (Figure 1). On 1st January 2020, the seafood market was closed and decontaminated while countries with travel links to Wuhan went on high alert for potential travelers with unexplained respiratory disease. After extensive speculation about a causative agent, the Chinese Center for Disease Control and Prevention (CDC) confirmed a report by the Wall Street Journal and announced identification of a novel CoV on 9th January [2]. The novel CoV (2019-nCoV) was isolated from a single patient and subsequently verified in 16 additional patients [3]. While not yet confirmed to induce the viral pneumonia, 2019-nCoV was quickly predicted as the likely causative agent. The first sequence of 2019-nCoV was posted online one day after its confirmation on behalf of Dr. Yong-Zhen Zhang and scientists at Fudan University, Shanghai [4]. Subsequently, five additional 2019-nCoV sequences were deposited on the GSAID database on 11th January from institutes across China (Chinese CDC, Wuhan Institute of Virology and Chinese Academy of Medical Sciences & Peking Union Medical College) and allowed researchers around the world to begin analyzing the new CoV [5]. By 17th January, there were 62 confirmed cases in China and importantly, three exported cases of infected travelers who were diagnosed in Thailand (2) and Japan (1) [6]. The sequences of these exported cases and several additional 2019-nCoV isolated in China have also been deposited on the GSAID database [5]. Diagnostic tests have subsequently been developed and some are being used on suspect cases identified in other locations including Vietnam, Singapore, and Hong Kong [7]. To date there have been twenty-six fatalities associated with 2019-nCoV infection, many of these cases had significant co-morbidities and were older in age (>50). A range of disease has been observed highlighted by fever, dry cough, shortness of breath, and leukopenia; patients have included mild cases needing supportive care to severe cases requiring extracorporeal membrane oxygenation; however, compared to SARS-CoV (10% mortality) and MERS-CoV (35% mortality), the 2019-nCoV appears to be less virulent at this point with the exception of the elderly and those with underlying health conditions. Initial monitoring of case close contacts had not revealed any further 2019-nCoV cases. However, modeling analysis based on official case numbers and international spread suggested that there may be cases going undetected [8]. On 19th January, these fears were seemingly confirmed as an additional 136 cases were added from further surveys raising the total in Wuhan to 198 infected patients [9]. Among the 198 total cases in Wuhan, 170 remained in hospitals, 126 mostly with mild symptoms, 35 in serious condition, and 9 in critical condition. The expanded numbers and extended range of onset dates (12 December 2019–18 January 2020) suggested likely human to human transmission or ongoing transmission from a market or other primary sources. On 20th January, the outbreak was further expanded to other parts of China (Beijing, Shanghai, & Shenzhen) as well as another exported cases to South Korea. As of January 24, the total case number has expanded to at least 870 total cases with 26 deaths across 25 provinces in China and 19 exported cases in 10 countries [10]. Public health authorities have quarantined travel from Wuhan to limit the spread of the virus and reports indicate other Chinese cities have also been isolated [11]. With the heavy travel season for lunar New Year underway in Asia, major concerns exist for the 2019-nCoV outbreak to continue and spread. 2. ORIGINS OF 2019-NCOV The source of the 2019-nCoV is still unknown, although the initial cases have been associated with the Huanan South China Seafood Market. While many of the early patients worked in or visited the market, none of the exported cases had contact with the market, suggesting either human to human transmission or a more widespread animal source [6]. In addition to seafood, it is reported on social media that snakes, birds and other small mammals including marmots and bats were sold at the Huanan South China Seafood Market. The WHO reported that environmental samples taken from the marketplace have come back positive for the novel coronavirus, but no specific animal association has been identified [6]. An initial report suggested that snakes might be the possible source based on codon usage [12], but the assertion has been disputed by others [13]. Researchers are currently working to identify the source of 2019-nCoV including possible intermediate animal vectors. A zoonotic reservoir harkens back to the emergence of both SARS- and MERS-CoV. SARS-CoV, the first highly pathogenic human CoV, emerged in 2002 with transmission from animals to humans occurring in wet markets. Surveillance efforts found SARS-CoV viral RNA in both palm civets and raccoon dogs sold in these wet markets [14]; however, SARS-CoV was not found in the wild, suggesting that those species served as intermediary reservoir as the virus adapted to more efficiently infect humans. Further surveillance efforts identified highly related CoVs in bat species [15]. More recent work has demonstrated that several bat CoVs are capable of infecting human cells without a need for intermediate adaptation [16,17]. Additionally, human serology data shows recognition of bat CoV proteins and indicates that low-level zoonotic transmission of SARS-like bat coronaviruses occurs outside of recognized outbreaks [18]. MERS-CoV is also a zoonotic virus with possible origins in bats [19,20], although camels are endemically infected and camel contact is frequently reported during primary MERS-CoV cases [21]. For SARS-CoV, strict quarantine and the culling of live markets in SE Asia played a major role in ending the outbreak. With the cultural importance of camels, a similar approach for MERS-CoV was not an option and periodic outbreaks continue in the Middle East. These lessons from SARS and MERS highlight the importance of rapidly finding the source for 2019-nCoV in order to stem the ongoing outbreak. 3. SUSCEPTIBLE POPULATIONS With limited patient data, it is difficult to make robust declarations about populations that may be most susceptible to 2019-nCoV. However, disease severity following SARS- and MERS-CoV corresponded strongly to underlying host conditions including age, biological sex, and overall health [22]. Early patient reports from 2019-nCoV find similar trends. Severe illness with 2019-nCoV has been associated with elderly patients (>60 years old), including twenty-six lethal cases. These findings correspond to increased severity and death in people over the age of 50 following both SARS and MERS-CoV infection